AZURE-Outcomes

Official Title: A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Sponsor: AstraZeneca

Conditions: Cardiovascular Disease

Brief Summary: The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.

Intervention / Treatment:

• Drug: AZD0780

• Drug: Placebo

Learn More: Additional details about this study are available on https://clinicaltrials.gov/study/NCT07000357

Questions or Interested in Participating? To learn more about participation at our site, please contact our study team:

(801) 584-5665 or submit an inquiry